Taikang invests in Chinese biologics startup

April 27 2018 by

Taikang Insurance has taken part in a US$150 million funding round for Innovent Biologics, a biotech company in China.

The series-E financing was led by Capital Group Private Markets (CGPM), which ...

To continue reading the full article and get full access to the InsuranceAsia News platform, please enquire about a subscription.

Your company may already have a corporate license in place.

Already a Subscriber? Please Login

MORE FROM: Health
Partner Content